Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of its comprehensive genomic profiling offerings with xF+, a new non-invasive, liquid biopsy panel of 523 genes, focused on pathogenic mutations in cell-free DNA (cfDNA). The test will originally be available on a limited basis alongside xF, Tempus’ 105-gene liquid biopsy assay, with a broader launch slated for later this year.
Tempus expects that the xF+ panel will be the largest clinically available liquid biopsy panel on the market, covering more genes with single nucleotide variants and indels reported in all genes, plus expanded coverage of translocations/gene rearrangements, and copy number variants. It can also measure blood-based tumor mutational burden (bTMB) and microsatellite instability (MSI), predictive biomarkers for response to various cancer immunotherapies. Liquid biopsies can be useful for parallel testing with tumor tissue to provide a more comprehensive detection of actionable alterations than tissue or liquid biopsy testing alone. Additionally, follow-up liquid biopsy testing can uncover new gene alterations and resistance mechanisms (clonal evolution), sample tumor DNA shed from metastatic sites, and can be used to longitudinally monitor disease burden and response to treatment.
“xF+ further strengthens Tempus’ range of genomic profiling capabilities, offering physicians a broad-panel liquid biopsy option for patients in which a comprehensive, non-invasive test is appropriate,” said Nike Beaubier, MD, Vice President of Translational Medicine at Tempus. “We are excited to introduce what we believe is the largest clinically available liquid biopsy panel to provide even more insights on pathogenic mutations in cfDNA.”
xF+ is the latest addition to Tempus’ library of assays, which includes xF; xT, an assay that analyzes 648 genes in solid tumor and hematologic malignancies; xG, a 52-gene panel that specifically identifies genetic variants associated with hereditary cancer syndromes and inherited risk of cancer; xG+, a 88-gene multi-cancer panel that covers genes associated with both common and rare hereditary cancer syndromes; and xE, an assay that analyzes the whole exome. All panels are run in Tempus’ CAP-accredited, CLIA-certified robotic sequencing labs.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit https://tempus.co/3azlvWr.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220603005051/en/
Copyright Business Wire 2022